Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Update of the guidelines on sudden cardiac death of the European Society of Cardiology

Open access
Priori, S · 2003 · European Heart Journal

Abstract

One of the most important challenges forscientific societies responsible for the development of guidelines, is to provide regular update of recommendations when new data become available. The Committee for Practice Guidelines of the ESC has set the goal of producing an update of guidelines every 12–24 months from the publication of the initial document (http://www.escardio.org). The guidelines for the prevention of suddencardiac death (SCD) were published in the August issue of the European Heart Journal in 20011 and the Executive Summary was published in theJanuary issue of Europace.2 In the last 12 months, the release of important data has affected risk stratification and management of patients at riskof dying suddenly. Based on this evidence, the members of the Task Force on SCD of the ESC have decided to revise the original document. Theupdated version of the full document will be published on the ESC website. Here, we review the evidence that has led to the update of two sections: (1) primary prevention of SCD in post-myocardial infarction (MI) and heart failure, and (2) primary prevention of SCD in dilated cardiomyopathy (DCM). The revision of the section of primary prevention of SCD in post-MI and heart failure has been considered appropriate based on the release of the results of the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) trial.3 This study was designed to investigate whether the implantable cardioverter defibrillator (ICD) would be effective in the prevention of all-cause death in patients with post-MI and low (≤30%) ejection fraction (EF). The study was based on the assumption that ICD would reduce all-cause death by 38% at 2-years with a 95% power and a probability value of 0.05. A randomization ratio of 3:2 to receive either an ICD or conventional medical therapy was selected.Analysis of primary endpoint was performed using a triangular sequential design, similar to the one adopted in the MADIT trial.4 After inclusion of 1232 patients, the MADIT II study was terminated because of a significant (31%) reduction in all-cause death in patients assigned to ICD therapy. MADIT II provides evidence that patients meeting the study entry criteria have a better survival if they receive a prophylactic ICD. The benefit was reflected in a 12, 28 and 28% death reduction at years 1, 2 and 3 of follow-up, respectively. Notably, the incidence of heart failure was higher (19.9%) in patients assigned to ICD than in patients receiving conventional therapy only (14.9%). Results of MADIT II suggest that ICD therapy may be indicated for primary prevention of all-cause death in patients post-MI with an EF≤30%. The members of the Task Force have carefully discussed how to incorporate the results of the present study in the recommendations for the use of the ICD in primary prevention of SCD in patients after MI and left ventricular dysfunction. The committee has agreed that, before a Class I recommendation is provided for ICD in post-MI patients with EF≤30%, it would be important that concordant results are obtained in at least another studyaddressing the same issue. The concern has been raised that early termination of the trial as a result of the triangular sequential design may have led to an overestimate of the long-term benefit of ICD therapy. It has also been argued that MADIT II does not include an antiarrhythmic drug arm. Specifically, amiodarone was not investigated based on negative findings obtained in previous trials in patients with congestive heart failure. However, it should be acknowledged that the population of patients in those earlier studies was different from that of the MADIT II as outlined by a rate of 70% of patients in NYHA class I or II in this latter trial. More information on the role of amiodarone is expected from an ongoing trial, the SCD-Heft, in which, however, entry criteria are substantially different from those used in the MADIT II. Furthermore, since Holter recording was notperformed in MADIT II, patients meeting MADIT4 criteria (i.e. spontaneous occurrence of non-sustained ventricular tachycardia (VTns) and inducible/non-suppressible ventricular tachycardia (VT) during programmed electrical stimulation) were not excluded from enrollment—the contribution of this subgroup of patients to the results of MADIT II therefore remains unclear. Furthermore, secondary endpoint analyses of MADIT II are ongoing: it is expected that they will provide data on the value of additional risk stratification parameters in this population of patients. Similarly, MADIT II investigators are expected to present data on the expected prolongation of life and the cost per ‘year of life saved’ of ICD in the MADIT II population. In summary, based on these considerations a recommendation for a Class IIa with a level of evidence B has been issued (Table 1). Primary prevention in post MI with or without HF MI—myocardial infarction; ACE—angiotensin converting enzyme; LV—left ventricular; V

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0195-0668x(02)00809-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 170

Metadata

Authors
Priori, S.
Venue
European Heart Journal
Published
2003-01
Volume
24
Issue
1
Pages
13-15
ISSN
0195-668X (ISSN-L)
OpenAlex
W2134203554
Cited by
170
References
1
FWCI
15.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update of the guidelines on sudden cardiac death of the European Society of Cardiology. https://app.cochat.ai/papers/10.1016/s0195-0668x(02)00809-6
The paper
Priori, S. (2003). Update of the guidelines on sudden cardiac death of the European Society of Cardiology. European Heart Journal. https://doi.org/10.1016/s0195-0668x(02)00809-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.